P3, N=300, Enrolling by invitation, Axsome Therapeutics, Inc.

P1, N=118, Recruiting, Vertex Pharmaceuticals Incorporated | Not yet recruiting --> Recruiting

P2, N=100, Recruiting, University of Michigan | Not yet recruiting --> Recruiting

A 79-year-old woman with suspected choroidal lesion underwent 18F-FDG PET/CT, which revealed a non-FDG-avid right thyroid lobe incidentaloma (4.8 cm in largest dimension) that was cold on 99mTc-thyroid scan, showed intense SSTR expression on 68Ga-DOTATATE PET/CT, and MIBG avidity on 131I-MIBG scan, thereby proving it to be of neural crest origin. Fine needle aspiration biopsy (FNAB) with immunohistochemistry was positive for GATA3 and synaptophysin and negative for CK7, PAX8, TTF1, and calcitonin, establishing the diagnosis of thyroid paraganglioma. Even though rare, the diagnosis of paraganglioma should be considered in SSTR and MIBG-avid thyroid nodules, as seen in this case.

P2, N=361, Completed, Duke University | Active, not recruiting --> Completed

Cyclophosphamide treatment induces profound suppression of ribosomal biogenesis, cytoplasmic translation, mitochondrial oxidative phosphorylation, and Wnt-associated regenerative programs in hair matrix cells, indicating a functional metabolic arrest preceding overt epithelial cell loss...Topical venlafaxine and its active metabolite desvenlafaxine preserved follicular architecture, suppressed apoptosis, and restored hair shaft elongation in both mouse CIA models and human hair follicle organ culture. At single-cell resolution, venlafaxine reversed epithelial translational shutdown, reactivated differentiation and Wnt signaling programs, and attenuated fibroinflammatory remodeling, thereby restoring paracrine niche signaling and matrix cell proliferation. Collectively, these findings redefine CIA as a disorder characterized by coordinated epithelial functional arrest and dermal inflammatory remodeling and identify venlafaxine as a potential pharmacological strategy to mitigate chemotherapy-associated hair loss.

Pharmacological inhibition of RBMS1 with nortriptyline (NTP) significantly attenuated renal fibrosis in unilateral ureteral obstruction (UUO) mice. These results reveal an RBMS1/ANXA8/PI3K/AKT regulatory axis in renal fibrosis, highlighting RBMS1 as a potential therapeutic target.

P4, N=100, Recruiting, Wake Forest University Health Sciences | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: May 2026 --> May 2027

P4, N=25, Recruiting, Hugo W. Moser Research Institute at Kennedy Krieger, Inc.

P=N/A, N=30, Completed, ISSSTE Hospital Regional "Gral. Ignacio Zaragoza" | Initiation date: Jan 2024 --> Jun 2024

P2, N=12, Recruiting, ConSynance Therapeutics | Not yet recruiting --> Recruiting

P=N/A, N=52, Not yet recruiting, Prince of Wales Hospital